For the first time, the U.S. Food and Drug Administration (FDA) has approved the use of a ketamine-like drug as a stand-alone therapy for adults with treatment-resistant depression (TRD).

This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. Jessica Mendoza: A quick heads up before we get started. This episode ...

Esketamine (a derivative of ketamine) nasal spray formulations can act fast and help reduce dangerous symptoms of major depression and suicidal thoughts found a new study. The findings of this ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for treatment-resistant depression. No More Pricking: US FDA Approves ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Tesla and SpaceX CEO Elon Musk clarified that he uses only "a small amount once every other week or something like that" ...

Coverage of the federal budget understandably focuses on the big-ticket items, from billions for housing or education to new health initiatives and cost-of-living relief.

A drug inspired by the anesthetic ketamine just became the first new kind of depression medication in 35 years. Called Spravato, a brand name for esketamine, and developed by Johnson & Johnson ...

When Welsh drag performer James Lee Williams appeared on the first season of RuPaul’s Drag Race UK in 2019 as The Vivienne, they made history and wowed fans by becoming the reality competition ...